A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY

Trial Profile

A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Ruxolitinib (Primary) ; Nilotinib
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Mar 2016 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016, as reported by ClinicalTrials.gov.
    • 04 Mar 2016 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016, as reported by ClinicalTrials.gov.
    • 22 Jun 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top